Bristol Myers: promising results in colorectal cancer
(CercleFinance.com) - Bristol Myers Squibb announces that results from a Phase 3 trial showed that Opdivo combined with Yervoy significantly improved progression-free survival compared with Opdivo monotherapy for the treatment of metastatic MSI-H/dMMR colorectal cancer.
With a median follow-up of 47 months, treatment combining Opdivo and Yervoy resulted in a 38% reduction in the risk of progression or death.
These results were presented at the ASCO Gastrointestinal Cancers symposium on 25 January 2025 and reported in The Lancet.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
With a median follow-up of 47 months, treatment combining Opdivo and Yervoy resulted in a 38% reduction in the risk of progression or death.
These results were presented at the ASCO Gastrointestinal Cancers symposium on 25 January 2025 and reported in The Lancet.
Copyright (c) 2025 CercleFinance.com. All rights reserved.